Reduction of AMPA receptor activity on mature oligodendrocytes attenuates loss of myelinated axons in autoimmune neuroinflammation

Kirsten S. Evonuk1, Ryan E. Doyle1, Carson E. Moseley2,3, Ian M. Thornell4,*, Keith Adler1, Amanda M. Bingaman1, Mark O. Bevensee4, Casey T. Weaver2, Booki Min5, Tara M. DeSilva1†

Glutamate dysregulation occurs in multiple sclerosis (MS), but whether excitotoxic mechanisms in mature oligodendrocytes contribute to demyelination and axonal injury is unexplored. Although current treatments modulate the immune system, long-term disability ensues, highlighting the need for neuroprotection. Glutamate is elevated before T2-visible white matter lesions appear in MS. We previously reported that myelin-reactive T cells provoke microglia to release glutamate from the system x̂− transporter promoting myelin degradation in experimental autoimmune encephalomyelitis (EAE). Here, we explore the target for glutamate in mature oligodendrocytes. Most glutamate-stimulated calcium influx into oligodendrocyte somas is AMPA receptor (AMPAR)–mediated, and genetic deletion of AMPAR subunit GluA4 decreased intracellular calcium responses. Inducible deletion of GluA4 on mature oligodendrocytes attenuated EAE and loss of myelinated axons was selectively reduced compared to unmyelinated axons. These data link AMPAR signaling in mature oligodendrocytes to the pathophysiology of myelinated axons, demonstrating glutamate regulation as a potential neuroprotective strategy in MS.

INTRODUCTION

Multiple sclerosis (MS) is a neuroinflammatory demyelinating disease of the central nervous system (CNS) that results in progressive disability by causing demise to myelin and axons. Damage to the myelin sheath impairs propagation of nerve impulses. Although myelin can be regenerated by oligodendrocyte progenitor cells (OPCs), this process is fairly inefficient, leaving axons vulnerable to injury and eventual degeneration. Most MS cases are diagnosed as relapsing-remitting, where disease symptoms develop, followed by periods of cessation termed remission. A relapse is defined as a clinical event involving the onset of neurological symptoms; however, the number of inflammatory events in the CNS is far greater than the number of relapses in patients with MS (1). This may explain why immunomodulatory drugs used to treat patients with MS initially reduce relapses and improve quality of life; yet, long-term disease progression still proceeds without remedy (2). Therefore, therapeutic interventions for CNS protection are necessary for long-term improvement. One such target is glutamate, which is thought to play an important role in the pathophysiology of MS.

Increased concentrations of glutamate in the cerebrospinal fluid (CSF) (3), plasma (4), and acute lesions (5) have been reported in patients with MS. Enhanced levels of glutamate in MS are associated with decreased brain volume (6). More recently, elevated levels of glutamate are detected before the appearance of new T2-visible white matter lesions, implicating glutamate as an important excitotoxin in MS (7). Consistent with these findings, we previously reported that myelin-reactive T cells provoke microglia to release glutamate from the system x̂− transporter, promoting myelin degradation in experimental autoimmune encephalomyelitis (EAE) (8). Here, we focus on the target for excitotoxic glutamate.

Similar to neurons, oligodendrocytes express ionotropic glutamate receptors that render them vulnerable to excitotoxicity, i.e., the pathological overstimulation of glutamate receptors resulting in calcium-mediated cell death. Excitotoxicity has been linked to MS by amelioration of EAE using AMPA-type glutamate receptor (AMPAR) antagonists administered by intraperitoneal injection (9, 10) and by global genetic deletion of the GluA3 AMPAR subunit (11). However, AMPAR expression on T cells regulates their activation (12) and chemotactic migration (13), which could modulate their effector function and their extravasation into the CNS. Furthermore, neurons express AMPARs, making it unclear whether damage to myelin is facilitated subsequent to neuronal dysfunction. Therefore, direct evidence of excitotoxicity specific to oligodendrocytes in EAE has not been demonstrated.

Excitotoxicity to oligodendrocytes is regulated through GluA2-free calcium-permeable AMPARs with a combination of subunits GluA1, GluA3, and GluA4 (14). Here, we show that GluA4 is robustly expressed on mature oligodendrocytes in the adult rodent consistent with their expression in the adult human white matter (15). We also found that most of the glutamate-stimulated calcium influx in oligodendrocyte cell bodies is AMPAR-mediated and Cre recombinase-mediated deletion of the GluA4 AMPAR subunit decreased calcium responses. Selective deletion of GluA4 on mature oligodendrocytes using inducible PLPcreER ameliorated clinical symptoms in the chronic phase of EAE. Consistent with diminished clinical severity, AMPAR-deficient mice had less myelin damage, a reduction in axonal loss, and a decrease in the production of amyloid precursor protein (APP) (a marker of axonal injury) in spinal cord white matter. To determine whether targeted deletion of AMPARs on mature oligodendrocytes specifically affected myelinated axons as opposed to unmyelinated axons in EAE, axonal integrity was evaluated at the ultrastructural level by electron microscopy. There was a statistically significant reduction in myelinated axons but not unmyelinated axons, suggesting that deletion of AMPARs on mature oligodendrocytes...
is selectively protective to axons with myelin. These data provide evidence that selectively deleting the AMPAR subunit GluA4 in mature oligodendrocytes not only reduces demyelination but also protects myelinated axons from injury in EAE. Thus, therapeutic strategies to regulate glutamate homeostasis have important clinical ramifications for protecting the CNS.

RESULTS
Inducible deletion of GluA4 impairs glutamate-induced AMPAR-mediated calcium signaling in the oligodendrocyte soma

We previously reported that microglia stimulated with interferon-γ and tumor necrosis factor–α (TNF-α) caused death of mature oligodendrocytes that could be attenuated by inhibiting an excitotoxic source of glutamate or blocking AMPARs with 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide (NBQX) but not N-methyl-D-aspartate (NMDA)–type glutamate receptors (NMDARs) with MK-801 (16). Consistent with these data, primary cultured mature oligodendrocytes loaded with the calcium-sensitive dye Fura-2 acetoxymethyl ester (AM) responded to glutamate stimulation, with an increase in intracellular calcium (Ca^{2+}) in the cell soma that was nearly completely inhibited by the AMPAR antagonist NBQX (93% inhibition, SEM ± 2%; fig. S1, A and D). We observed a similar inhibition with NBQX after stimulation with the AMPA agonist (97% inhibition, SEM ± 1%; fig. S1, B and D). The glutamate response elicited in primary mature oligodendrocytes was partially inhibited by the noncompetitive NMDAR antagonist MK-801 (40% inhibition, SEM ± 7%; fig. S1, C and D). On the basis of these experimental results and a lack of efficacy in NMDAR deletion in reducing EAE symptoms (16), we used PLPcreER mice in which tamoxifen-inducible cre expression is driven under control of the oligodendrocyte-specific PLP promoter (17) to delete the AMPAR subunit GluA4 specifically from mature oligodendrocytes in adult mice. The GluA4^{−/−} mouse line was previously characterized using a neuron-specific cre, which significantly reduced AMPAR currents (18). Oligodendrocytes express GluA4 throughout development (19, 20), and GluA4 is abundant in adult human white matter (15), rodent spinal cord white matter (21), and rodent optic nerve oligodendrocytes (22). These data indicate that GluA4 deletion in mature oligodendrocytes will decrease AMPAR-mediated Ca^{2+} influx. Therefore, we tested the hypothesis that targeted deletion of GluA4 in oligodendrocytes reduces AMPAR-mediated calcium influx. In the spinal cord white matter of adult PLPcreER^{−/−};GluA4^{−/−} mice, GluA4 expression (2 weeks after tamoxifen induction) was substantially reduced in mature oligodendrocytes somas compared to PLPcreER^{−/−};GluA4^{+/−} mice (Fig. 1A and quantification in fig. S2A) but remained unchanged in glial fibrillary acidic protein (GFAP) immunoreactive astrocytes (Fig. 1B and quantification in fig. S2B) and a subset of motor neurons (Fig. 1C and quantification in fig. S2C). Furthermore, quantification of GluA4 in ionized calcium binding adaptor molecule 1 (Iba1) immunoreactive myeloid cells (fig. S2, D and F) and any cellular structure negative for adenomatous polyposis coli clone CC1 (CC1) (fig. S2E) was also not statistically different. Expression of GluA1-3 in oligodendrocytes remained unchanged (quantified in fig. S2A and images in fig. S3). Transcript expression of GluA1-4 reflected the results found at the protein level with a statistically significant reduction in Gria4 but not Gria1-3 (fig. S4A). As reduced AMPAR signaling due to deletion of GluA4 could result in compensatory expression of other ionotropic glutamate receptor subunits, we next explored whether a reduction of GluA4 affected the expression of kainate and NMDARs (fig. S4, B and C). No compensatory up-regulation was observed; however, Grik3, encoding the GluK3 (GluR7) kainate receptor subunit, was significantly reduced in PLPcreER^{−/−};GluA4^{−/−} compared to PLPcreER^{−/−};GluA4^{+/−} white matter. Expression of NMDAR subunit transcript was unchanged (fig. S4C).

To demonstrate AMPA/kainite receptor–mediated Ca^{2+} responses in oligodendrocytes ex vivo, we preincubated optic nerves from PLPcreER^{−/−};GluA4^{−/−};tdTomato and PLPcreER^{−/−};GluA4^{+/−};tdTomato mice with Oregon Green 488 BAPTA-1 (OGB-1), a fluorescent calcium indicator. After stimulation with glutamate, fluorescent TdTomato oligodendrocytes exhibited an increase in Ca^{2+} in the cell soma (Fig. 2, A and B) that was largely inhibited by the AMPA/kainite receptor antagonist NBQX (Fig. 2, B to D). Ex vivo optic nerves from PLPcreER^{−/−};GluA4^{−/−};tdTomato mice showed a statistically significant reduction in maximum and overall Ca^{2+} in the cell soma compared to PLPcreER^{−/−};GluA4^{+/−};tdTomato in response to glutamate that was principally blocked by NBQX (Fig. 2, B to D). These data provide evidence that selective deletion of GluA4 in oligodendrocytes confers a functional impairment in AMPA/kainite receptor–mediated intracellular calcium in the cell soma in response to glutamate.

Inducible deletion of GluA4 from mature oligodendrocytes in adult mice using PLPcreER ameliorates clinical scores and reduces myelin degradation in EAE

Constitutive deletion of AMPARs during development results in a reduction in myelin thickness (23). To avoid confounding developmental defects in myelination, adult mice were tamoxifen-induced to selectively delete GluA4 in mature oligodendrocytes. To further confirm that inducible deletion of GluA4 in mature myelin does not affect myelin/axonal integrity in naïve mice, we performed electron microscopy of spinal cord white matter from 9-week-old PLPcreER^{−/−};GluA4^{−/−} [knockout (KO)] and PLPcreER^{−/−};GluA4^{+/−} littermate control [wild-type (WT)] mice 3 weeks after tamoxifen induction. The g-ratio (ratio of axon diameter to axon and myelin diameter) measurements (fig. S5, A to C) and cumulative frequency distribution of g-ratios (fig. S6A) revealed no statistical difference between WT and KO, providing evidence that myelin thickness in the lumbar ventral white matter of the spinal cord was unaltered in KO mice. In addition, lumbar ventral white matter axons in KO mice had normal percentage of myelinated (fig. S5D) and unmethylated (fig. S5E) axons, and total number of axons was unchanged (fig. S5F).

Axon diameter was also normal as indicated by no shift in cumulative frequency distribution of myelinated (fig. S6B) or unmethylated (fig. S6C) axons. Together, these results suggest that myelin and axons are unaltered in naïve animals after inducible deletion of GluA4 from mature oligodendrocytes. To determine whether AMPARs mediate excitotoxic damage to myelin during autoimmune neuroinflammation, we subjected adult 9-week-old PLPcreER^{−/−};GluA4^{−/−} (KO) and PLPcreER^{−/−};GluA4^{+/−} littermate control (WT) mice to EAE 2 weeks after tamoxifen induction to activate recombination. EAE was significantly less severe in mice deficient in AMPAR function selectively on mature oligodendrocytes (KO) compared to control (WT) (Fig. 3A). To confirm that the specificity of PLPcreER for oligodendrocytes was not affected after EAE, we stained spinal cords from PLPcreER^{−/−};GluA4^{−/−};tdTomato mice with anti-neuronal nuclei (NeuN), anti-GFAP, and anti-Iba1. TdTomato did not colocalize
Fig. 1. The GluA4 AMPAR subunit is reduced in adult spinal cord oligodendrocytes from PLPcreER + ;GluA4 fl/fl compared to PLPcreER − ;GluA4 fl/fl mice. Mice were tamoxifen-induced at 6 weeks of age and euthanized for immunofluorescence staining at 8 weeks of age. Representative confocal images of PLPcreER + ;GluA4 fl/fl (WT) versus PLPcreER − ;GluA4 fl/fl (KO) mouse lumbar spinal cords. (A) Images taken in lateral funiculus white matter. Far-red (pseudocolored magenta) immunofluorescence represents anti-GluA4 (first column). Green immunofluorescence represents the mature oligodendrocyte marker anti-CC1 (second column). Blue fluorescence represents the nuclear marker bisbenzimide (third column). All images are merged in the final column (Merge). (B) Images taken in lateral funiculus white matter. Far-red (pseudocolored magenta) immunofluorescence represents anti-GluA4 (first column). Green immunofluorescence represents the astrocyte marker anti-GFAP (second column). All images are merged in the final column (Merge). (C) Images taken in ventral gray matter. Far-red (pseudocolored magenta) immunofluorescence represents anti-GluA4 (first column). Green immunofluorescence represents the neuronal marker NeuN (second column). Blue fluorescence represents the nuclear marker bisbenzimide (third column). All images are merged in the final column (Merge). Images are representative of $n = 4$ mice per genotype. Scale bars, 10 µm.
with neurons (NeuN), astrocytes (GFAP), or microglia (Iba1) (fig. S7). Furthermore, expression of AMPARs after EAE induction (fig. S8) was consistent with the expression found before induction of EAE (fig. 1 and fig. S3). To evaluate whether KO mice had a reduction in myelin damage compared to WT in the chronic phase of EAE (35 days after EAE induction), we quantified anti–myelin basic protein (MBP) 3,3′-diaminobenzidine (DAB) staining of spinal cord myelin. We observed a significantly higher optical density (OD) of myelin staining in total lumbar spinal cord white matter of AMPAR-deficient mice compared to control (fig. 3, B to E), indicating that AMPARs mediate excitotoxic damage to myelin in autoimmune neuroinflammation. To determine whether a reduction in myelin damage influenced reactive gliosis, we assessed DAB staining for astrocytes (anti–GFAP) and the myeloid lineage (anti–Iba1) in whole spinal cord sections. Percent area for astrocyte staining was not significantly reduced in KO mice compared to control (fig. 3, F to I), while anti–Iba1 staining was statistically decreased in the lumbar region (fig. 3, J to M). Previous studies have shown that markers of the myeloid lineage correlate with removal of myelin debris (24). Together, these data suggest that a functional reduction in AMPAR-mediated intracellular calcium responses reduced excitotoxic damage to myelin.

**Inducible deletion of GluA4 from mature oligodendrocytes in EAE reduces axonal damage**

Inducible deletion of GluA4 selectively in mature oligodendrocytes attenuated clinical scores consistent with myelin preservation in adult mice subjected to EAE. To investigate whether blocking AMPAR-mediated excitotoxicity to myelin affects axon integrity, we used three-dimensional (3D) reconstruction of axons in PLPcreER−;GluA4fl/fl (WT) and PLPcreER−;GluA4fl/fl;tdTomato+ (KO) mice 35 days after EAE induction. In the lumbar ventral white matter, where demyelination is prominent during EAE, loss of SMI-312–immunopositive axons was apparent in WT compared to KO mice in the chronic phase of EAE (day 35 after EAE induction; fig. 4). We also observed irregularities in axonal organization and size in WT compared to KO mice (fig. 4, A to C, and movies S1 and S2). Swollen axons indicative of the presence of axonal ovoids (fig. 4, B and C) as described in postmortem MS brains (25) were prevalent in WT compared to KO mice. KO mice exhibited a statistically significant preservation of axon number (fig. 4D). To further explore axonal damage, we performed immunostaining of anti–APP (APP A4) staining in the lumbar spinal cord white matter (fig. 5A). APP accumulation in axons results from axonal damage (26), and we observed APP+ puncta colocalized with axons (fig. 5, C to E). Furthermore, we found a reduced number of APP+ puncta in the dorsal column white matter of KO mice compared to WT mice (fig. 5B). However, in the ventral white matter where there is a substantial loss of axons (fig. 4), no difference in the number of APP+ puncta was detected. These data are consistent with other studies demonstrating the transient nature of APP expression in MS and EAE lesions, with greater accumulation in acute lesions than in chronic lesions, suggesting that when there is loss of axons, there is loss of APP+ puncta (27).

To test the hypothesis that selectively deleting AMPAR function on mature oligodendrocytes confers protection to myelinated axons as opposed to unmyelinated axons in EAE, we performed assessments at the ultrastructural level. We first assessed the lumbar ventral white matter, where demyelination is prominent during EAE, with toluidine blue, which only stains myelinated axons. KO EAE mice had preserved numbers of myelinated axons compared to WT EAE mice (fig. 6, A and B). We used electron microscopy to assess the total number of axons, including myelinated as opposed to unmyelinated axons. Consistent with observations by confocal 3D reconstruction (fig. 4), the total number of axons was higher in KO compared to WT EAE mice (fig. 6C). Furthermore, consistent with...
This study demonstrates that a functional reduction in AMPAR activity on mature oligodendrocytes ameliorates clinical presentation, reduces myelin damage, and specifically attenuates loss of myelinated axons in EAE. Selective deletion of the GluA4 AMPAR subunit on oligodendrocytes reduced calcium responses in the cell soma but did not affect myelin or axonal integrity in naive mice. Therefore, these data support that the AMPAR is a conduit for glutamate-induced calcium influx into mature oligodendrocytes to facilitate excitotoxic damage to myelin and a concomitant loss of axons in a model of autoimmune inflammatory demyelination. Furthermore, our data show that selectively reducing AMPAR signaling in myelin promotes axonal integrity, particularly providing protection to myelinated axons as demonstrated by ultrastructural analysis and providing evidence, at least in part, that damage to axons is secondary to myelin damage in EAE.

Although glutamate is essential for excitatory synaptic transmission, overstimulation of ionotropic glutamate receptors is a pathological process initiating excessive calcium influx that results in excitotoxicity to neurons. This is an important mechanism involved in neurodegenerative diseases. Oligodendrocytes also express ionotropic glutamate receptors and are vulnerable to excitotoxicity (14). In animal models of perinatal hypoxic-ischemic injury, damage to developing oligodendrocytes was blocked by AMPAR and NMDAR antagonists (28, 29). Although immunofluorescence studies in the rodent and human brain have shown that GluR2-lacking AMPARs (which confer calcium permeability) are more highly expressed on developing oligodendrocytes (19, 20), mature myelinating oligodendrocytes in the adult brain are vulnerable to AMPAR-mediated excitotoxic damage induced by chemical ischemia and AMPAR agonists (22, 30, 31). During chemical ischemia in adult white matter, AMPARs mediate excitotoxic damage to the cell body, whereas NMDARs mediate excitotoxic damage to the myelin sheath (30), providing a specific regional organization after maturation. Our ex vivo calcium imaging data demonstrate that genetic deletion of the GluA4 AMPAR subunit decreased calcium responses in the oligodendrocyte cell body. This is not only consistent with a statistically significant decrease in GluA4 protein expression but may also be partially attributed to the reduction in the low-affinity kainite receptor 3 (Grik3). Glutamate-stimulated calcium influx was nearly completely blocked by NBQX, an AMPA/kainite receptor antagonist, indicating an AMPA/kainite receptor-mediated response. In primary mature oligodendrocytes cultured from rodent forebrain, we also show that glutamate-stimulated calcium influx into the soma was...
also nearly completely blocked with NBQX. Protein expression and calcium influx are not completely abolished in AMPA/kainite receptor–deficient oligodendrocytes, which may serve important signaling roles necessary for normal physiology (23).

While most of the glutamate-stimulated calcium influx in the oligodendrocyte soma appeared to be AMPA/kainite receptor–mediated, approximately 40% of the calcium influx was blocked by the NMDAR antagonist MK-801. Previous studies have also reported NMDAR responses in the mature soma of oligodendrocytes (32). Together, these data suggest that in the oligodendrocyte soma, the AMPA/kainite receptor may be the gateway for activation of the NMDAR. This is similar to observations in neurons, where AMPAR activation is necessary to depolarize the cell membrane and relieve the magnesium block to facilitate NMDAR-mediated calcium influx. However, deletion of the obligatory NR1 NMDAR subunit selectively on oligodendrocytes did not attenuate EAE (16). In light of the current study, there may be several explanations for this. Over-

activation of NMDARs is highly excitotoxic to neurons, which are composed of the conventional heteromeric subunits NR1 and NR2A-D. On the contrary, oligodendrocytes express a unique NMDAR subunit composition. NMDARs on oligodendrocytes contain the NR3 subunit that confers a reduction in calcium permeability (32). Oligodendrocytes also express NR1/NR3 excitatory glycine receptors that are not activated by glutamate (33). In addition, if the predominant expression of NMDARs resides in the mature myelin sheath, perhaps the small volume of the mature process restricts calcium influx and its effect on mature oligodendrocytes as a whole. Each oligodendrocyte’s mature myelinating processes can ensheathe multiple axons, making damage to the oligodendrocyte soma amplificatory.

Factors that contribute to the excitotoxic vulnerability of AMPARs must be considered in EAE and MS. The system x c − transporter imports cystine for the biosynthesis of glutathione in exchange for export of glutamate (34). We previously demonstrated that an important link between inflammation and glutamate dysregulation in autoimmune inflammatory demyelination is the system x c − transporter, which is highly up-regulated on microglia as a consequence of T cell activation and promotes myelin degradation (8). In addition, we showed that CNS-infiltrating macrophages highly express system x c −, making its contribution to the excitotoxic pool of glutamate highly relevant in EAE. Similarly, activated monocytes from patients with MS also

Fig. 4. Inducible reduction of AMPAR signaling in mature oligodendrocytes attenuates axonal loss in EAE. (A to C) Alpha-blended 3D representations of confocal z-stacks (112.71 μm by 112.71 μm by 9.00 μm) of spinal cord ventral funiculus from PLPcreER−;GluA4fl/fl (WT; first column) and PLPcreER+;GluA4fl/fl (KO; second column) mice. Far-red (pseudocolored magenta) immunofluorescence represents anti–SMI-312 (neurofilament), and green immunofluorescence represents anti-MBP. Top-down view in (A) and (B) and angled view in (C). (D) Quantification of SMI-312+ axons per cubic millimeter (means ± SEM), n = 6 WT and 8 KO mice, 3 to 4 3D z-stacks from two sections per mouse euthanized 35 days after EAE induction. Statistical differences were determined using a two-tailed unpaired t test, *P = 0.0248.

Fig. 5. Inducible reduction of AMPAR signaling in oligodendrocytes attenuates axonal damage in EAE. (A) Anti–APP A4 staining of lumbar dorsal white matter. Scale bars, 50 μm. (B) Quantification of anti–APP A4+ puncta in dorsal white matter of lumbar spinal cords (means ± SEM), n = 6 PLPcreER−;GluA4fl/fl (WT) and 8 PLPcreER+;GluA4fl/fl (KO) mice, 2 to 4 sections per mouse, euthanized 33 days after EAE induction. Statistical differences were determined using a two-tailed unpaired t test, *P = 0.0412. (C) Colocalization of anti–APP A4 with anti–SMI-312 (neurofilament) in WT mouse spinal cord white matter. Red (pseudocolored cyan) immunofluorescence represents anti–APP A4 (first column), Far-red (pseudocolored magenta) immunofluorescence represents anti–SMI-312 (second column). Anti–APP A4 and anti–SMI-312 are merged in the third column (Merge 1). Green immunofluorescence represents anti-MBP (fourth row). All images are merged in the final column (Merge 2). Images are representative of n = 3 WT mice. Scale bars, 10 μm. (D and E) Magnified images of APP+ /SMI-312+ axons in the spinal cord white matter of WT mice. Scale bars, 5 μm.
up-regulate and release glutamate through the system $x^-$. Moreover, we previously showed that pharmacological inhibition of system $x^-$ after disease onset and immune cell infiltration reduces symptoms of EAE and results in increased myelin integrity (8), demonstrating that targeting a source of excitotoxic glutamate is neuroprotective. 

Several studies present compelling evidence that the major regulators of extracellular glutamate are down-regulated in MS and animal models of MS. Excitatory amino acid transporters (EAATs) are extremely efficient in maintaining glutamate homeostasis; however, genetic perturbations in glutamate transporter expression are known to promote excitotoxicity (36). Proinflammatory cytokines, particularly TNF-$\alpha$ implicated in the pathology of MS and EAE (37, 38), reduced glutamate transporter expression and function (39, 40). In rodents subjected to EAE, protein expression of glutamate transporters was further reduced, implicating glutamate as an important excitotoxin to the development of lesions in patients with MS (7).
transporters was reduced (41, 42). In white matter from patients with MS, expression of EAAT1 and EAAT2 was diminished in the perimeter of early and chronic active lesions (43). These data support the hypothesis that excess extracellular glutamate cannot be properly regulated by glutamate transporters.

Published data also provide evidence that inflammation enhances excitotoxicity. The cytokine TNF-α enhanced excitotoxic death of oligodendrocytes (44). Exposure to TNF-α also increased the surface expression of calcium permeable AMPARs in cultured hippocampal neurons (45). A similar phenomenon was reported in MS lesions, where GluA1 was found to be up-regulated in oligodendrocytes, while the expression of GluA2, which reduces calcium permeability when present, remained unchanged (46). This suggests that in inflammatory states, oligodendrocytes may be more susceptible to the effects of excitotoxicity than during normal physiological conditions. While infiltrating immune cells have been documented in MS brains and animal models of EAE providing a strong link between inflammation and glutamate dysregulation in cerebral white matter, diffuse reactive gliosis has also been documented in gray matter regions in MS (47). This suggests that while infiltrating immune cells produces an acute excitotoxic lesion in white matter, there may be a more subtle imbalance in glutamate homeostasis that contributes to the long-term gray matter atrophy observed in patients with MS.

Newly proliferated OPCs that appear in lesions from human MS postmortem brains and animal model of MS may also be vulnerable to excitotoxic mechanisms or hyperactivation of glutamate receptors. This may cause death of OPCs, reducing the number available for remyelination, or lock OPCs in an undifferentiated state. A significant reduction in the number of OPCs was observed in chronic active lesions from MS brains, attributed to a change in migration and/or death (48). Another study illustrated differentiated oligodendrocytes in lesion sites that do not appear to form mature myelin, surmising an interruption in maturation (49). In a toxin-mediated model of demyelination, AMPAR activity on newly proliferated OPCs was required for remyelination (50). Glutamate dysregulation is not expected in the aforementioned model; however, these data support that perturbations in glutamate homeostasis as observed in the EAE model may perturb the remyelination process. Thus, approaches to regulating glutamate homeostasis may reduce demyelination and promote remyelination. Our studies used inducible deletion of the GluA4 AMPAR in the adult mouse using the PLPcreER promoter to target mature myelin. However, future studies that target AMPARs in newly proliferated OPCs in inflammatory models of demyelination would be of interest.

Axonal damage is one of the best predictors of disability in MS (51); therefore, preventing demyelination and/or promoting remyelination has important implications for the preservation of axonal integrity. In the present study, we observed decreased clinical symptoms in the chronic phase of EAE consistent with reduced demyelination and loss of myelinated axons in mice with targeted deletion of AMPAR function in mature oligodendrocytes. Hypomyelinated axons are more susceptible to excitotoxic damage than myelinated axons (52), suggesting that damage to oligodendrocytes can enhance susceptibility of axons to excitotoxicity and other insults. In addition, oligodendrocytes provide metabolic support to axons in the form of lactate, suggesting that disruption of myelin can interrupt this support mechanism (53). In our study, only myelinated axon numbers were affected by AMPAR deletion from mature oligodendrocytes, indicating that for myelinated axons in EAE, axonal damage may be secondary to myelin damage.

In the present study, we also observed reduced immunostaining for Iba1 in spinal cords from AMPAR-deficient mice compared to controls subjected to EAE but not GFAP (a marker of astrocytes). In our study, clinical scores were reduced in the chronic phase of the disease in AMPAR-deficient mice concomitant with improved myelinated axon integrity. Previous studies have shown that markers of the myeloid lineage correlate with disease severity and removal of myelin debris (24). Therefore, our observed reduction in Iba1-immunopositive staining is likely a consequence of reduced damage to myelin and axons. Alternatively, single-cell analysis of postmortem MS brains and spinal cords from mice induced with EAE shows that oligodendrocytes express many genes associated with immune responses (54), suggesting the possibility that preventing myelin damage may contribute to altered inflammatory responses (55). It is also possible that glutamate signaling in oligodendrocytes via the AMPAR could alter oligodendrocyte immune responses; for example, by altering expression of major histocompatibility complex molecules, pattern recognition receptors, chemokine receptors, or chemokines and cytokines. Disruption of any of these signaling factors could decrease oligodendrocyte-microglia cross-talk, thereby dampening microglial activation as observed in the PLPcreER−/−;GluA4fl/fl EAE mice. How and whether AMPAR signaling plays a role in oligodendrocyte and microglial interactions will require further investigation.

There is limited evidence that current therapies available for MS prevent disease progression (2), advocating for the discovery of targets that can protect the CNS during inflammatory events. Our results indicate that a reduction in AMPAR function in mature oligodendrocytes reduces not only demyelination but also axonal loss in EAE, emphasizing glutamate dysfunction as an important underlying neurodegenerative mechanism in MS. Since glutamatergic homeostasis is critical for normal physiological processes, many considerations must be made in regard to therapeutic efficacy. In addition, clinically approved drugs that target ionotropic receptors tend to be partial antagonists. Since NMDAR activation occurs downstream of AMPAR, perhaps a combination approach would be more advantageous. In addition, treatment strategies that regulate glutamate homeostasis would likely benefit as add-on therapies to currently prescribed immune modulators in MS. Overall, these data provide the first direct evidence that blocking AMPAR-mediated excitotoxicity selectively to myelin attenuates axonal demise, providing a promising therapeutic target for neurodegeneration in MS.

**MATERIALS AND METHODS**

**Primary cultures and calcium imaging of mature oligodendrocytes**

Oligodendrocytes were obtained from postnatal day (P) 2 or P3 Long-Evans rats as previously described (8, 56). Purified oligodendrocytes were plated onto poly-β-DL-ornithine–coated glass coverslips in 12-well plates and maintained in basal-defined media [Dulbecco’s minimum essential medium containing 4 mM L-glutamine, 1 mM pyruvate, bovine serum albumin (1 mg/ml), human apo-transferrin (50 mg/ml), bovine pancreatic insulin (5 mg/ml), 30 nM sodium selenite, 10 nM D-biotin, and 10 nM hydrocortisone] supplemented with recombinant basic fibroblast growth factor (10 ng/ml; PeproTech, Rocky Hill, NJ) and human platelet-derived growth factor (10 ng/ml; PeproTech) for 7 days. To promote differentiation into mature...
from Hooke Laboratories (Lawrence, MA). Intraperitoneal injections of Tamoxifen, MD) or using a custom emulsion containing the same doses in incomplete Freund's adjuvant (Becton, Dickinson and Company, Sparks, MD) was performed as previously described (57). Mature oligodendrocytes on coverslips were loaded with the calcium-sensitive Fura-2 dye by exposing cells to the standard artificial CSF (aCSF; 140 mM NaCl, 5 mM KCl, 1.5 mM CaCl₂, 1.5 mM MgCl₂, 10 mM Hepes, and NaOH to pH 7.4 at 37°C) containing 5 to 10 μM of the cell-permeant Fura-2 AM and 0.01% of the dispersing agent Pluronic F-127 (Invitrogen, Molecular Probes, Grand Island, NY) for 15 to 40 min at 37°C. An individual coverslip was mounted and formed on the base of a flow-through perfusion chamber (RC-25, Warner Instruments, Hamden, CT). The chamber was then secured to the stage of an IX-70 inverted Olympus microscope with an attached high-speed wavelength changer (Lambda DG-4, Sutter Instrument, Novato, CA) and a mounted digital charge-coupled device camera (Orcia II, Hamamatsu, Bridgewater, NJ). The temperature of the perfusate was maintained at ~37°C by an automatic temperature controller (TC-334B, Warner Instruments).

Animals
Male and female mice on the C57BL/6J background were used for EAE experiments. B6.Cg-Tg(Plp1-cre/ERT)3Pop/J (referred to as PLPcreER; 005975, the Jackson laboratory) mice were crossed with Gria4tm1Mony mice (18) on a C57BL/6 background provided by H. Monyer at Heidelberg University (referred to as GluA4). For cre-driven expression of the red fluorescent protein tdTomato, mice were bred with B6;129S6-Gt(ROSA)26Sor tm14(CAG-tdTomato)Hze/J mice (referred to as tdTomato; 007908, the Jackson laboratory). EAE was performed on 8- to 10-week-old PLPcreER mice. Littermate controls were used for all experiments. Animals were housed and treated in accordance with National Institutes of Health (NIH) and the Institutional Animal Care and Use Committee guidelines of the University of Alabama at Birmingham and the Cleveland Clinic.

Tamoxifen induction
PLPcreER mice and littermate controls received intraperitoneal injections of tamoxifen (20 mg/ml) (approximately 75 mg/kg; T5648, Sigma-Aldrich, St. Louis, MO) in 100 μl of peanut oil every day for 5 days, 2 to 3 weeks before induction of EAE. For calcium imaging experiments that used PLPcreER+;tdTomato+ mice at P9, one intraperitoneal injection of 30 μl of tamoxifen (10 mg/ml) in peanut oil was given at P3.

EAE induction and scoring
Mice were induced with EAE as previously described (8) using a 200-μl emulsion containing 50 μg of myelin oligodendrocyte glycoprotein 35-55 (CPC Scientific, Sunnyvale, CA) and 125 μg of desiccated Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit, MI) in incomplete Freund’s adjuvant (Becton, Dickinson and Company, Sparks, MD) or using a custom emulsion containing the same doses from Hooke Laboratories (Lawrence, MA). Intraperitoneal injections of 200 ng of Bordetella pertussis toxin (List Biological Laboratories, Campbell, CA or Hooke Laboratories, Lawrence, MA) in phosphate-buffered saline (PBS) were administered on days 0 and 2 of induction. Mice were scored daily for symptoms of EAE using the following scale: 0, no symptoms; 1, loss of tail tone; 2, flaccid tail; 3, partial hind limb paralysis; 4, complete hind limb paralysis; 5, moribund state (humanely euthanized); and 6, death.

Perfusion and preparation of mouse spinal cords for immunohistochemistry
Spinal cords from mice were removed following transcardiac perfusion with 4% paraformaldehyde (PFA) in PBS, postfixed overnight, and cryopreserved in 30% sucrose. For adult mice, spinal cords were decalcified in 0.5 M EDTA in PBS (pH 7.8) for 3 weeks before cryopreservation. Spinal cords were cut into six pieces and embedded in a solution of one part 30% sucrose in PBS/two parts Optimal Cutting Temperature (OCT) Compound embedding medium (Fisher HealthCare, Waltham, MA). Sections were cut on a cryostat at 16 μm (or 30 μm for confocal 3D reconstructions).

DAB immunohistochemistry
Antigen retrieval was performed using 10 mM citrate buffer (pH 3) at 37°C for 30 min. Sections were blocked in 5% serum corresponding to the host of the secondary antibody with 0.3% Triton X-100 in PBS for 30 min to 1 hour at room temperature. Primary antibodies were diluted in blocking buffer and incubated on sections overnight at 4°C. Biotinylated secondary antibodies were diluted in blocking buffer and incubated on sections for 1 hour at room temperature. Endogenous peroxidase activity was blocked by incubating slices in 0.3% hydrogen peroxide in methanol for 10 min at room temperature. Antibodies were visualized using the avidin-biotin-immunoperoxidase complex (ABC) method using the VECTASTAIN ABC Kit (PK-4000, Vector Laboratories, Burlingame, CA) and DAB Peroxidase (horse-radish peroxidase) Substrate Kit (SK-4100, Vector Laboratories, Burlingame, CA). Slides were dehydrated and mounted in Permount (SP15, Thermo Fisher Scientific, Waltham, MA). Primary antibodies included goat polyconal anti-MBP (D-18) immunoglobulin G (IgG) (1:1000; sc-13912, Santa Cruz Biotechnology, Dallas, TX), mouse anti-GFAP IgG2b (1:1000; 835301, BioLegend, San Diego, CA), rabbit anti-Iba1 (1:750; 019-19741, Wako, Richmond, VA), and rabbit anti-APP A4 [Y188] IgG (1:750; ab32136, Abcam, Cambridge, UK). Biotinylated secondary antibodies were used at a dilution of 1:200 and included horse anti-mouse IgG (BA-2000, Vector Laboratories, Burlingame, CA), goat anti-rabbit IgG (BA-1000, Vector Laboratories, Burlingame, CA), and horse anti-goat IgG (BA-9500, Vector Laboratories, Burlingame, CA).

Immunofluorescence
Antigen retrieval was performed on anti-GluA3 and anti-Iba1 immunofluorescence sections using 10 mM citrate buffer (pH 3) at 37°C for 30 min. Sections were blocked in 5% serum corresponding to the host of the secondary antibody with 0.3% Triton X-100 in PBS (PBS alone for anti-GluA3) for 1 hour at room temperature. Primary antibodies were diluted in blocking buffer and incubated on sections overnight at 4°C or for 4 hours at room temperature. Secondary antibodies (biotinylated for anti–GluA1-3 and antibodies stained with DyLight 405; fluorescence conjugated for all others) were diluted in blocking buffer and incubated on sections for 1 hour at room temperature. For tissue treated with biotinylated
secondary antibodies, fluorescence-conjugated streptavidin was diluted in washing buffer and incubated on sections for 30 min at room temperature. Slides were mounted with Fluoromount-G (0100-01, SouthernBiotech, Birmingham, AL) containing bisbenzimide (1:1000; H3569, Invitrogen, Carlsbad, CA) where applicable.

Primary antibodies included mouse anti-CC1 (1:200; OP80, Calbiochem/MilliporeSigma, Burlington, MA), goat polyclonal anti-MBP (D-18) IgG (1:250; sc-13912, Santa Cruz Biotechnology, Dallas, TX), mouse anti-NeuN IgG1 (1:750; MAB377, EMD Millipore, Billerica, MA), mouse anti-GFAP IgG2b (1:1000 or 1:600 with DyLight 405; 835301, BioLegend, San Diego, CA), rabbit anti-Iba1 (1:750 or 1:500 with DyLight 405; 019-19741, Wako, Richmond, VA), goat anti-Iba1 (1:200; ab107159, Abcam, Cambridge, UK), rabbit anti-GluA1 (1:500; AB1504, EMD Millipore, Billerica, MA), mouse anti-GluA2 IgG2a (1:100; MAB397, EMD Millipore, Billerica, MA), rabbit anti-GluA2 (1:200; AB1768-I, EMD Millipore, Billerica, MA), rabbit anti-GluA3 (1:25; 4676S, Cell Signaling Technology, Danvers, MA), rabbit anti-GluA4 (1:300; AB1508, EMD Millipore, Billerica, MA), rabbit anti-APP A4 (Y188) IgG (1:500; ab32136, Abcam, Cambridge, UK), and mouse anti-neurofilament marker (SMI-312) IgG1/IgM (1:2000; 837901, BioLegend, San Diego, CA).

Biotinylated secondary antibodies were used at 1:200 and included horse anti-mouse IgG (BA-2000, Vector Laboratories, Burlingame, CA) and goat anti-rabbit IgG (BA-1000, Vector Laboratories, Burlingame, CA). Fluorescence-conjugated secondary antibodies were used at 1:1000 or 1:500 (all from Invitrogen, Carlsbad, CA) and included Alexa Fluor 488 goat anti-mouse IgG (A11001), Alexa Fluor 488 goat anti-rabbit IgG (A11034), Alexa Fluor 488 donkey anti-goat IgG (A11055), Alexa Fluor 488 goat anti-mouse IgG/IgM (A10680), Alexa Fluor 594 goat anti-rabbit IgG (A11037), Alexa Fluor 647 goat anti-mouse IgG (A21235), Alexa Fluor 647 goat anti-rabbit IgG (A21245), and Alexa Fluor 647 donkey anti-rabbit IgG (A31573). Fluorescence-conjugated streptavidins (all from Invitrogen) included streptavidin protein DyLight 488 (1:1000; 212832), Alexa Fluor 647–conjugated streptavidin (1:1000; lyophilized stock diluted 1 mg/ml in PBS; S21374), and streptavidin protein DyLight 405 (1:500; 21831).

**Imaging**

DAB immunohistochemical images were acquired using a Leica DM5500 B upright microscope with 5x objective and Leica DFC425 C digital camera with Leica Application Suite (version 4.4.0) acquisition software or a Leica SCN400 slide scanner at ×40 magnification. Toluidine blue staining images were acquired using a Leica SCN400 slide scanner at ×40 magnification. Fluorescent confocal images were acquired using a Nikon C2 confocal microscope system (Nikon, Melville, NY) with NIS-Elements software (Nikon, Melville, NY). Confocal images for 3D reconstruction were captured with 0.3-μm step size using the following objectives: Plan Fluor 40x/1.30 numerical aperture (NA) (oil immersion) and Apo 60x/1.40 NA (oil immersion). An advanced noise removal algorithm was applied evenly across experimental groups. For electron microscopy, grids were examined on a Tecnai G2 SpiritBT transmission electron microscope (FEI Company, Hillsboro, OR) operated at 60 kV.

**Quantification of glutamate receptor subunits by immunohistochemistry**

Percent area staining of AMPAR subunits GluA1-4 was calculated for cells containing bisbenzimide in four fields per animal taken from four sections including every fifth serial 16-μm section. Confocal images were taken at ×40 magnification with 170 μm by 170 μm fields for CC1, GFAP, and Iba1 and 200 μm by 200 μm fields for NeuN. Manual thresholding was performed using NIS-Elements software (Nikon, Melville, NY) in a blinded manner after background subtraction to identify staining for GFAP- and Iba1-immunopositive processes, for CC1- or NeuN-immunopositive cells containing bisbenzimide, and to detect area of GluA1-4 staining. For quantification of GluA4 in CC1− cells, bisbenzimide in the absence of CC1 immunoreactivity was used to identify CC1− cells, and GluA4 surrounding bisbenzimide was considered GluA4/CC1+. Cells were counted in a blinded manner using NIH ImageJ software, 1.48v.

**Quantitative real-time reverse transcription polymerase chain reaction analysis**

Optic nerves were removed from mice after transcardiac perfusion with cold, sterile PBS, and RNA was extracted using the RNeasy Mini Kit (74104, QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. RNA concentration was measured using a NanoDrop One (Thermo Fisher Scientific, Waltham, MA), and any remaining DNA contamination was removed by treatment with deoxyribonuclease I (18068015, Invitrogen, Carlsbad, CA). The complementary DNA was synthesized using TaqMan Reverse Transcription Reagents (N8080234, Invitrogen, Carlsbad, CA). Quantitative real-time reverse transcription polymerase chain reactions (PCR) were made using TaqMan Fast Advanced Master Mix (4445566, Applied Biosystems, Foster City, CA) and predeveloped TaqMan gene expression probes. Reactions were analyzed on a QuantStudio 6 Flex Real-Time PCR System using QuantStudio 6 software (Applied Biosystems, Foster City, CA). Samples were run in triplicate for each gene, and data were averaged for analysis. Fold change was calculated as 2−ΔΔCt compared to PLPcreER−/−;GluA4+/− (WT) values. Gene expression levels were normalized to glyceraldehyde-3-phosphate dehydrogenase.

**Quantification of reactive gliosis**

Percent area stained with Iba1 and GFAP antibodies were analyzed in thoracic and lumbar spinal cord sections using the free NIH ImageJ software, 1.48v, as previously described (8, 58). Briefly, images were converted to 16 bit, and whole spinal cords were traced. The rolling ball with sliding paraboloid method set to a radius of 4.0 pixels for Iba1 and 50.0 pixels for GFAP was used for background subtraction. Threshold was set to the same baseline across experimental groups to measure area of cellular staining. Assessments were made on every fifth section from 16-μm serial sections from the lumbar and thoracic regions of the spinal cord.

**Quantification of MBP staining**

OD of MBP staining was analyzed in thoracic and lumbar spinal cord sections using the free NIH ImageJ software, 1.48v, as previously described (38). Briefly, white matter regions of the spinal cord were traced, and mean gray values were obtained from every fifth section from 16-μm serial sections from the lumbar and thoracic regions of the spinal cord. These values were converted into OD values using the following formula, as described in the ImageJ User Guide IJ 1.46r: OD = log10 (255/mean gray value).

**Quantification of APP-immunopositive puncta**

Numbers of APP+ puncta were counted in lumbar spinal cords of PLPcreER−;GluA4 mice using the free NIH ImageJ software, 1.48v.
Calcium imaging was performed on the basis of previously described protocols (59, 60). PLPcreER<sup>+</sup>;GluA4<sub>fl/fl</sub>;tdTomato<sup>+</sup> and PLPcreER<sup>−</sup>;GluA4<sub>fl/fl</sub>;tdTomato<sup>+</sup> mice were tamoxifen-induced at P3. P9 mice were anesthetized with isoflurane and decapitated, and optic nerves were removed and placed in aCSF containing 126 mM NaCl, 26 mM NaHCO<sub>3</sub>, 3.0 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 2.0 mM MgSO<sub>4</sub>, 2.0 mM CaCl<sub>2</sub>, and 10 mM dextrose (pH 7.4), bubbled with carbogen (5% CO<sub>2</sub>/95% O<sub>2</sub>) for 20 min, and retested for pH. Nerves were then incubated for 2 hours in aCSF with 40 μM OGB-1 AM (O6807, Invitrogen, Carlsbad, CA) at room temperature with constant carbogen bubbling. Optic nerves were washed in aCSF and mounted in a perfusion chamber with a glass bottom made of a #1 coverslip. The chamber was perfused with room-temperature carbenogated aCSF and 10 μM cyclothiazide (CTZ; 0713, Tocris Bioscience, Bristol, UK) and mounted on a Nikon Eclipse Ti-S inverted microscope (Nikon, Melville, NY), with Nikon C2 confocal microscope system (Nikon, Melville, NY). Glutamate (100 μM; G1626, Sigma-Aldrich, St. Louis, MO) and NBQX (100 μM; 1044, Tocris Bioscience) were used for stimulation with CTZ (10 μM). Between stimulation with glutamate + CTZ and NBQX + glutamate + CTZ, optic nerves were given a 10-min recovery period in aCSF + CTZ. Time-lapse images were taken at 4.3- to 10-s intervals using a Plan Fluor 40×/1.30 NA (oil immersion) objective. OGB-1 was excited at 488 nm. Intensity of green fluorescence was normalized as ∆F/F<sub>0</sub> = [(F<sub>F</sub> − F<sub>B</sub>) − (F<sub>0</sub> − F<sub>B</sub>)]/(F<sub>0</sub> − F<sub>B</sub>), where F<sub>0</sub> was background, and F<sub>B</sub> was mean fluorescence signal in a baseline period that included the first 30 s before stimulus. Absolute calcium levels were not reported. Data were analyzed using NIS-Elements software (Nikon, Melville, NY) and Microsoft Excel. For analysis, only tdTomato<sup>+</sup> oligodendrocyte cell bodies were traced and fluorescence intensity was measured.

**Quantification of SMI-312–immunopositive axons**

Numbers of SMI-312<sup>+</sup> axons in the ventral white matter of PLPcreER<sup>+</sup>;GluA4<sub>fl/fl</sub> and PLPcreER<sup>−</sup>;GluA4<sub>fl/fl</sub> mouse spinal cords were measured from 3D reconstructions of immunofluorescence staining. Confocal 3D 133 μm by 133 μm by 25.50 μm z-stacks were subjected to blinded manual thresholding, and numbers of axons were automatically counted with NIS-Elements software (Nikon, Melville, NY). Objects with a volume of less than 0.015 μm<sup>3</sup> and a sphericity of less than 0.350 were removed from analyses, as these objects were determined to be nonaxonal. Assessments were made on every fifth serial 30-μm section, with four fields from two sections (including right and left ventral white matter).

**Toluidine blue staining and electron microscopy preparation**

Mice were perfused with 4% PFA, 2% glutaraldehyde in 0.1 M sodium cacodylate buffer at pH 7.4. Spinal cords were removed, and lumbar regions were processed by the Cleveland Clinic Electron Microscopy Core. Tissue was postfixed in 1% osmium tetroxide in water, stained with 1% uranyl acetate in maleate buffer (pH 5.1), and dehydrated with ethanol and propylene oxide before being embedded in Pure Eponate 12 resin (Ted Pella Inc., Redding, CA). Semithin 1-μm sections were cut with a diamond knife and stained with toluidine blue for analysis by light microscopy. Ultrathin 85-nm sections were cut with a diamond knife, stained with uranyl acetate and lead citrate, and observed with a transmission electron microscope.

**Analysis of toluidine blue**

Six 74.53 μm by 60.43 μm fields across the ventral funiculus of the spinal cord were analyzed per mouse. All myelinated axons in each field were counted and calculated as number of axons per square millimeter.

**Analysis of electron microscopy**

Six 20.75 μm by 13.68 μm images taken at ×6800 magnification were used to measure g-ratios in naïve mice. All myelinated axons in each image were traced in ImageJ 1.52i, and g-ratios were calculated as axon diameter divided by axon and myelin diameter. Six 49.35 μm by 32.54 μm images taken at ×2900 magnification were used to count axons in naïve and EAE mice across the ventral funiculus of the spinal cord. All axons in each image were counted and calculated as number of axons per square millimeters.

**Calcium imaging in ex vivo optic nerves**

Calcium imaging was performed on the basis of previously described protocols (59, 60). PLPcreER<sup>+</sup>;GluA4<sub>fl/fl</sub>;tdTomato<sup>+</sup> and PLPcreER<sup>−</sup>;GluA4<sub>fl/fl</sub>;tdTomato<sup>+</sup> mice were tamoxifen-induced at P3. P9 mice were anesthetized with isoflurane and decapitated, and optic nerves were removed and placed in aCSF containing 126 mM NaCl, 26 mM NaHCO<sub>3</sub>, 3.0 mM KCl, 1.25 mM NaH<sub>2</sub>PO<sub>4</sub>, 2.0 mM MgSO<sub>4</sub>, 2.0 mM CaCl<sub>2</sub>, and 10 mM dextrose (pH 7.4), bubbled with carbogen (5% CO<sub>2</sub>/95% O<sub>2</sub>) for 20 min, and retested for pH.
C. J. Azevedo, J. Kornak, P. Chu, M. Sampat, D. T. Okuda, B. A. Cree, S. J. Nelson, S. L. Hauser, D. Pelletier, In vivo evidence of glutamate toxicity in multiple sclerosis. Ann. Neurol. 76, 269–278 (2014).

A. M. Klauser, O. T. Wiebenga, A. C. J. Eijlers, M. M. Schoonhoven, B. M. J. Uitdehaag, F. Barkhof, P. J. W. Pouwels, J. J. G. Geurts, Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis. Mult. Scler. 24, 491–500 (2018).

K. S. Evonuk, B. J. Baker, R. E. Doyle, C. E. Moseley, C. M. Sestero, B. P. Johnston, Y. Ganor, M. Besser, N. Ben-Zakay, T. Unger, M. Levite, Human T cells express a functional Aalpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor that intensify demyelination in experimental autoimmune encephalomyelitis. J. Neurochem. 102, 1064–1070 (2007).

A. A. Boldyrev, V. I. Kazey, T. A. Leinsoo, A. P. Mashkina, O. V. Tyulina, P. Johnson, A. A. Boldyrev, V. I. Kazey, T. A. Leinsoo, A. P. Mashkina, O. V. Tyulina, P. Johnson, Developmental regulation of Aalpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex. J. Comp. Neurol. 497, 42–60 (2006).

D. M. Talos, P. L. Follett, R. E. Fishman, F. L. Trachtenberg, J. J. Volpe, F. E. Jensen, Developmental regulation of Aalpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex. J. Comp. Neurol. 497, 61–77 (2006).

S. Li, K. P. Stys, Mechanisms of ionotropic glutamate receptor-mediated excitotoxicity in isolated spinal cord white matter. J. Neurosci. 20, 1190–1198 (2000).

C. Mateu, M. V. Sánchez-Gómez, L. Martínez-Millán, R. Milladi, Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes. Proc. Natl. Acad. Sci. U.S.A. 94, 8830–8835 (1997).

E. Kougiontzidou, T. Shimizu, B. N. Hamilton, K. Tohyama, R. Sprengel, H. Monyer, D. Attwell, Implications for excitotoxicity in multiple sclerosis. Nature 467, 153–159 (2000).

D. J. Newcombe, A. Uddin, R. Dove, B. Patel, L. Turski, Y. Nishizawa, J. Smith, Glutamate receptor and GABA receptor trafficking by tumor necrosis factor-α in multiple sclerosis. J. Neurosci. 25, 3219–3228 (2005).

J. Newcombe, A. Uddin, R. Dove, B. Patel, L. Turski, Y. Nishizawa, J. Smith, Glutamate receptor expression in multiple sclerosis lesions. Brain Pathol. 18, 52–61 (2008).

C. F. Lucchetti, B. F. G. Popescu, R. F. Bunyan, N. M. Soll, F. Re, H. Lassmann, W. Brück, J. E. Parisi, B. W. Scheithauer, C. Giannini, S. D. Weigand, J. Mandrekar, R. M. Ransohoff, Inflammatory cortical demyelination in early multiple sclerosis. N. Engl. J. Med. 365, 2188–2197 (2011).

A. Boyd, H. Zhang, A. Williams, Insufficient OPC migration into demyelinated lesions is a cause of poor remyelination in MS and mouse models. Acta Neuropathol. 125, 841–859 (2013).

A. Chang, W. W. Tourellotte, R. Rudick, B. D. Trapp, Premyelinating oligodendrocytes are highly vulnerable to N-acetyl aspartate loss and reduced N-acetylaspartate in chronic multiple sclerosis patients. Ann. Neurol. 68, 893–901 (2000).

D. Pitt, E. Gonzales, A. H. Cross, M. P. Goldberg, Dysmyelinated axons in shiverer mice are highly vulnerable to Aalpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor-mediated toxicity. Brain Res. 1309, 146–154 (2010).
Evonuk et al., Sci. Adv. 2020; 6 : eaax5936  8 January 2020

53. Y. Lee, B. M. Morrison, Y. Li, S. Lengacher, M. H. Farah, P. N. Hoffman, Y. Liu, A. Tsingalia, L. Jin, P.-W. Zhang, L. Pellerin, P. J. Magistretti, J. D. Rothstein, Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature 487, 443–448 (2012).

54. A. M. Falcao, D. van Bruggen, S. Marques, M. Meijer, S. Jäkel, E. A. Agirre, S. Samudyata, E. M. Floriddia, D. P. Vanichkina, C. French-Constant, A. Williams, A. O. Guerreiro-Cacais, G. Castelo-Branco, Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat. Med. 24, 1837–1844 (2018).

55. L. Peferoen, M. Kipp, P. van der Valk, J. M. van Noort, S. Amor, Oligodendrocyte-microglia crosstalk in the central nervous system. Immunology 141, 302–313 (2014).

56. T. M. DeSilva, A. Y. Kabakov, P. E. Goldhoff, J. J. Volpe, P. A. Rosenberg, Regulation of glutamate transport in developing rat oligodendrocytes. J. Neurosci. 29, 7898–7908 (2009).

57. C. M. McNicholas-Bevensee, K. B. DeAndrade, W. E. Bradley, L. J. Dell'Italia, P. A. Lucchesi, M. O. Bevensee, Activation of gadolinium-sensitive ion channels in cardiomyocytes in early adaptive stages of volume overload-induced heart failure. Cardiovasc. Res. 72, 262–270 (2006).

58. K. S. Evonuk, C. E. Moseley, R. E. Doyle, C. T. Weaver, T. M. DeSilva, Determining immune system suppression versus CNS protection for pharmacological interventions in autoimmune demyelination. J. Vis. Exp. 2016, 654348 (2016).

59. Y. Ren, A. Ridsdale, E. Coderre, P. K. Stys, Calcium imaging in live rat optic nerve myelinated axons in vitro using confocal laser microscopy. J. Neurosci. Methods 102, 165–176 (2000).

60. N. Hamilton, P. S. Hubbard, A. M. Butt, Effects of glutamate receptor activation on NG2-glia in the rat optic nerve. J. Anat. 214, 208–218 (2009).

Acknowledgments: We would like to thank J. Drazba, Director of the Cleveland Clinic Imaging Core for assistance. Funding: This study was supported by National Multiple Sclerosis Society, RG 4587-A-1; NSF, 1648822; National Eye Institute, RO1EY025687 and T32 EY024326-02; National Institute of Allergy and Infectious Diseases, T32 AI007051-39; National Institute of Neurological Disorders and Stroke, P30-NS069324; National Multiple Sclerosis Society Postdoctoral Fellowship, FG-1807-31882; and the Mike L. Jezdimir Transverse Myelitis Foundation. Author contributions: K.S.E. and T.M.D. conceived the study and designed the experiments. I.M.T. performed and analyzed the in vitro calcium imaging experiments under the supervision of M.O.B. K.S.E. performed and analyzed calcium imaging experiments in ex vivo optic nerves. C.E.M., C.T.W., and B.M. contributed to the design and interpretation of the EAE experiments. K.S.E. and R.E.D. performed and analyzed EAE experiments. K.A. and A.M.B. contributed to immunocytochemistry. K.S.E. and T.M.D. drafted the manuscript. M.O.B., B.M., and I.M.T. were involved in editing and discussion. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. The GluA4fl/fl mouse line can be provided by H. Monyer at the University of Heidelberg pending scientific review and a completed material transfer agreement. Requests for the GluA4fl/fl mouse line should be submitted to H. Monyer at the University of Heidelberg. Additional data related to this paper may be requested from the authors.

Submitted 5 April 2019
Accepted 8 November 2019
Published 8 January 2020
10.1126/sciadv.aax5936

Citation: K. S. Evonuk, R. E. Doyle, C. E. Moseley, I. M. Thornell, K. Adler, A. M. Bingaman, M. O. Bevensee, C. T. Weaver, B. Min, T. M. DeSilva, Reduction of AMPA receptor activity on mature oligodendrocytes attenuates loss of myelinated axons in autoimmune neuroinflammation. Sci. Adv. 6, eaax5936 (2020).